The prognostic value of aspartate beta-hydroxylase in early breast cancer-Reference-Cited by-同舟云学术

The prognostic value of aspartate beta-hydroxylase in early breast cancer

Published:2022-06-20 Issue:3 Volume:37 Page:328-335
ISSN:0393-6155
Container-title:The International Journal of Biological Markers
language:en
Short-container-title:Int J Biol Markers

Author:

Barboro Paola¹^ORCID,Rubagotti Alessandra²,Poddine Silvia³,Grillo Federica⁴⁵,Mastracci Luca⁴⁵,Boccardo Francesco³

Affiliation:

1. Proteomic and Mass Spectrometry Unit, IRCCS Ospedale Policlinico San Martino, 16132, Genoa, Italy

2. Department of Health Sciences (DISSAL), School of Medicine, University of Genoa, 16132 Genoa, Italy

3. Department of Medicine and Medical Specialties (DIMI), School of Medicine, University of Genoa, 16132, Genoa, Italy

4. Anatomic Pathology Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy

5. Department of Surgical and Integrated Diagnostic Sciences (DISC), University of Genoa, 16132, Genoa, Italy

Abstract

Purpose Aspartate beta-hydroxylase (ASPH) is a transmembrane protein involved in cancer progression, which has been shown to imply a worse prognosis in several solid tumors. The aim of the present study was to further investigate the prognostic value of ASPH in early breast cancer. Methods ASPH expression was investigated through immunohistochemistry in a cohort of 153 breast cancer patients with long-term follow-up, and correlated with clinical–pathological features plus all-cause and breast-cancer-specific mortality. Appropriate statistics were utilized. Results ASPH negatively correlated with all-cause and breast-cancer-specific mortality. Conclusions The results of this cohort study support the prognostic value of ASPH in early breast cancer.

Funder

Supported by Italian Ministry of Health funds

Publisher

SAGE Publications

Subject

Cancer Research,Clinical Biochemistry,Oncology,Pathology and Forensic Medicine

Link

http://journals.sagepub.com/doi/pdf/10.1177/03936155221108412

Reference15 articles.

1. Cancer statistics, 2014

2. Insights from a Long-Term Follow-Up Evaluation of Early Breast Cancer Outcomes by Tumor Subtype

3. Diverse molecular functions of aspartate β‑hydroxylase in cancer (Review)

4. Aspartate β-hydroxylase targeting in castration-resistant prostate cancer modulates the NOTCH/HIF1α/GSK3β crosstalk